Ahold Delhaize $40M Drug-Pricing Settlement Puts Grocery Pharmacies In The Medicare And Medicaid Ledger

BadPD source-check, June 20, 2026; source dates June 10, June 12, June 18, 2026: The U.S. Department of Justice says Ahold Delhaize USA Inc. agreed to pay the United States and participating states $40 million to resolve False Claims Act and state-law allegations involving prescription-drug prices reported to federal healthcare programs.

The settlement is not a court finding of liability. DOJ says the resolved claims are allegations only, and the settlement agreement says it is neither an admission of liability by Ahold Delhaize USA nor a concession by the United States or the whistleblower that their claims were not well founded. That posture matters, because the accountability question is about billing controls, auditability, and public-program payment integrity, not a criminal conviction.

What DOJ Says Happened

DOJ says Ahold Delhaize supermarkets with in-store retail pharmacies operated prescription savings programs that gave enrolled members discounted prices on prescription drugs. The government contended that, under applicable Medicare Part D, Medicaid, and TRICARE requirements, those discounted prices should have been reported as the pharmacies’ usual and customary prices when claims were submitted to the federal healthcare programs.

Instead, DOJ says Ahold Delhaize pharmacies allegedly failed to accurately report discounted prices as usual and customary prices, causing Medicare Part D, Medicaid, and TRICARE to pay inflated amounts. The chains named in DOJ’s release include Giant, Hannaford, Stop & Shop, Food Lion, and others.

The core public-service issue is simple: if a pharmacy offers a lower price through its own savings program, federal health programs and state Medicaid programs need accurate price reporting so taxpayers are not billed above the real ceiling price. A private discount program should not become a higher public reimbursement lane.

What The Settlement Agreement Adds

The settlement agreement gives the tighter ledger. It identifies Ahold Delhaize USA Inc., Ahold U.S.A. Inc., Delhaize America LLC, The GIANT Company LLC, Giant of Maryland LLC, The Stop & Shop Supermarket Company LLC, Food Lion LLC, and Hannaford Bros. Co. LLC as ADUSA parties. It says the whistleblower case was filed by Lawrence LaBenne in the Western District of Pennsylvania in 2018.

The agreement separates two covered-conduct windows: May 2013 through September 2017 for Legacy Ahold prescription savings programs, and January 2009 through October 2016 for Legacy Delhaize prescription savings programs. The government contends the discounted program prices should have been reported as usual and customary prices and that failure to do so caused Medicare Part D, Medicaid, and TRICARE to pay inflated amounts.

The $40 million settlement breaks down as $32,884,253 plus interest to the United States and $7,115,747 plus interest to Medicaid participating states. The federal settlement amount includes $16,442,127 in restitution. The agreement says the relator is to receive $6,083,587 plus a pro rata share of actual interest from the federal share, and the company also agreed to pay $765,000 in relator counsel fees and costs.

Consumer And Public-Money Angle

This is not only a Department of Justice finance story. It sits inside ordinary grocery-pharmacy shopping. Stop & Shop, Giant, Hannaford, Food Lion, and related brands are consumer-facing pharmacy brands, and the allegations involve the difference between what customers could pay under savings programs and what public healthcare programs were allegedly told was the usual-and-customary price.

CT Insider localized the issue for Stop & Shop readers and reported that Ahold Delhaize did not admit wrongdoing. Grocery Dive reported Ahold Delhaize’s statement that it admitted no wrongdoing, fully cooperated, and described the billing questions as tied to programs discontinued nearly a decade ago. Those company-response facts should stay in the article because they define the settlement posture.

Confirmed, Alleged, Pending

Confirmed by official records: Ahold Delhaize USA agreed to a $40 million federal/state settlement; the settlement resolves False Claims Act and state-law allegations; DOJ identifies Medicare Part D, Medicaid, and TRICARE claims; the settlement includes a federal share, a state share, a restitution component, a relator award, and unallowable-cost provisions; the agreement reserves certain rights and is conditioned on payment terms.

Alleged or settlement posture: inflated usual-and-customary prices, underreporting discounted prescription savings prices, and any claim that federal or state programs overpaid because of those prices remain civil allegations resolved without a liability determination. Ahold Delhaize’s no-admission posture remains part of the source trail.

Missing records to verify: payment confirmation, state-by-state Medicaid allocation, pharmacy claims audit summaries, claim-count or prescription-level totals, PBM or Part D sponsor contract language, compliance-control changes, customer notice if any, pharmacy program discontinuation records, corporate compliance monitoring, and whether any administrative action, exclusion review, or follow-on state enforcement appears after the civil settlement.

BadPD Bottom Line

This is a clean consumer-accountability and public-program integrity receipt. The official story is not that a court found fraud after trial. The official story is that a national grocery-pharmacy operator agreed to pay $40 million to resolve allegations that its pharmacies reported inflated usual-and-customary prices to Medicare Part D, Medicaid, and TRICARE.

BadPD will update the ledger if DOJ, HHS-OIG, state Medicaid agencies, or court records disclose payment proof, state allocations, compliance obligations, claim-level totals, or follow-on enforcement. The key follow-up is whether the settlement changes pharmacy billing controls so public programs receive the same practical pricing reality customers see at the counter.

Source Trail

• DOJ USAO Western District of Pennsylvania: Ahold Delhaize USA Inc. to Pay $40M for Allegedly Reporting Inflated Drug Prices (June 10, 2026; updated June 18, 2026) – Primary official release with settlement amount, federal/state split, alleged usual-and-customary price conduct, relator award, and no-liability caveat.
• DOJ settlement agreement PDF: Ahold Delhaize USA / LaBenne FCA settlement (June 2026) – Primary settlement agreement identifying released entities, covered conduct periods, payment mechanics, federal restitution amount, state payment, reserved claims, unallowable-cost treatment, and no-admission language.
• CT Insider: Stop & Shop parent company agrees to pay $40 million to settle pharmacy pricing suit (June 18, 2026) – Regional report tying the settlement to Stop & Shop customers and summarizing the whistleblower, state/federal split, and no-wrongdoing posture.
• Grocery Dive: ADUSA to pay $40M for allegedly reporting inflated drug prices (June 12, 2026) – Industry report with brand/pharmacy context, Ahold Delhaize statement, and business-practice context around discontinued programs.